Patient Stories in PAH: Sequential Therapy in a FC II Patient
Program Goals
Case Study 53-Year-Old Man With IPAH
Case Study History
Case Study (cont) History
Now, 17 Months Later
Repeat RHC Findings
Sequential Combination Therapy Recommendations for WHO FC II PAH Patients
Pharmacologic Agents for PAH 3 Pathways
Rationale for Combination Therapy
GRIPHON
GRIPHON Treatment Effect by Subgroup
GRIPHON Titration and Dosing
Primary Composite Endpoint in Patients Grouped by Prespecified Selexipag Individual Maintenance Dose vs Placebo
Case Summary
Abbreviations